Your browser is no longer supported. Please, upgrade your browser.
Settings
ANAB AnaptysBio, Inc. daily Stock Chart
ANAB [NASD]
AnaptysBio, Inc.
Index- P/E- EPS (ttm)-2.71 Insider Own0.30% Shs Outstand27.32M Perf Week-1.79%
Market Cap674.92M Forward P/E- EPS next Y-2.25 Insider Trans0.00% Shs Float27.14M Perf Month-9.92%
Income-73.80M PEG- EPS next Q1.06 Inst Own- Short Float14.65% Perf Quarter52.33%
Sales18.00M P/S37.50 EPS this Y-43.90% Inst Trans-2.96% Short Ratio11.40 Perf Half Y32.94%
Book/sh13.19 P/B1.96 EPS next Y-82.90% ROA-17.90% Target Price28.00 Perf Year94.49%
Cash/sh12.93 P/C1.99 EPS next 5Y- ROE-19.10% 52W Range12.06 - 31.28 Perf YTD58.71%
Dividend- P/FCF- EPS past 5Y- ROI-26.40% 52W High-17.56% Beta0.16
Dividend %- Quick Ratio14.10 Sales past 5Y-12.80% Gross Margin- 52W Low113.85% ATR1.70
Employees89 Current Ratio14.10 Sales Q/Q- Oper. Margin- RSI (14)51.08 Volatility5.76% 6.17%
OptionableYes Debt/Eq0.00 EPS Q/Q24.10% Profit Margin- Rel Volume0.49 Prev Close24.68
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume348.57K Price25.79
Recom2.50 SMA20-8.18% SMA5013.16% SMA20035.87% Volume169,426 Change4.50%
Oct-27-20Upgrade Wedbush Neutral → Outperform $35
Oct-14-20Upgrade Guggenheim Neutral → Buy $36
Nov-08-19Downgrade Wedbush Outperform → Neutral
Nov-08-19Downgrade SunTrust Buy → Hold
Nov-08-19Downgrade JP Morgan Overweight → Underweight $109 → $17
Nov-08-19Downgrade Jefferies Buy → Hold $12
Jun-21-19Downgrade Stifel Buy → Hold $124 → $74
Jun-21-19Downgrade Credit Suisse Outperform → Neutral $137 → $79
Dec-20-18Initiated H.C. Wainwright Buy $126
Nov-21-18Initiated JP Morgan Overweight $115
Jul-19-18Initiated Credit Suisse Outperform $104
Apr-04-18Downgrade RBC Capital Mkts Outperform → Sector Perform
Mar-27-18Reiterated Stifel Buy $139 → $152
Mar-06-18Reiterated Stifel Buy $130 → $139
Feb-15-18Reiterated SunTrust Buy $115 → $162
Jan-23-18Reiterated Credit Suisse Outperform $85 → $135
Nov-15-17Initiated SunTrust Buy $115
Nov-09-17Initiated Jefferies Buy $101
Oct-11-17Reiterated RBC Capital Mkts Outperform $40 → $79
Sep-15-17Initiated RBC Capital Mkts Outperform $40
Nov-13-20 09:25AM  
Nov-04-20 04:00PM  
Oct-26-20 11:54PM  
08:00AM  
Oct-16-20 09:00AM  
Oct-14-20 04:19PM  
10:03AM  
Oct-13-20 09:00AM  
Oct-05-20 06:48AM  
Sep-28-20 06:43PM  
Sep-11-20 04:05PM  
Sep-01-20 07:36PM  
Aug-24-20 09:30AM  
Aug-21-20 09:24AM  
Aug-10-20 09:25AM  
08:05AM  
08:00AM  
Aug-06-20 12:30PM  
Aug-05-20 04:05PM  
Jul-31-20 08:30AM  
Jul-18-20 08:27PM  
Jul-15-20 08:30AM  
Jul-09-20 08:09AM  
Jul-07-20 12:29PM  
Jul-02-20 08:48PM  
Jun-22-20 12:00PM  
Jun-15-20 08:59AM  
Jun-10-20 11:30AM  
Jun-09-20 06:09PM  
May-27-20 07:33AM  
May-26-20 12:40PM  
12:10PM  
10:50AM  
10:49AM  
09:36AM  
May-25-20 10:50PM  
03:50PM  
02:30PM  
02:20PM  
01:00PM  
11:30AM  
10:35AM  
10:00AM  
09:08AM  
08:00AM  
07:40AM  
May-24-20 07:35PM  
01:48PM  
May-23-20 03:30PM  
02:30PM  
May-22-20 10:50PM  
05:45PM  
03:55PM  
03:15PM  
03:00PM  
02:15PM  
01:47PM  
01:21PM  
11:18AM  
10:43AM  
09:37AM  
May-21-20 08:00PM  
05:00PM  
03:00PM  
01:11PM  
01:00PM  
01:00PM  
12:00PM  
10:32AM  
09:28AM  
06:20AM  
May-20-20 10:50PM  
02:30PM  
02:00PM  
01:46PM  
12:16PM  
11:30AM  
11:18AM  
10:00AM  
09:24AM  
06:20AM  
May-19-20 10:50PM  
05:44PM  
04:34PM  
01:50PM  
01:00PM  
12:40PM  
12:15PM  
11:45AM  
07:05AM  
May-18-20 10:50PM  
09:30PM  
09:30PM  
08:33PM  
02:40PM  
02:20PM  
01:45PM  
06:25AM  
May-17-20 05:02PM  
12:51PM  
AnaptysBio, Inc., a clinical stage biotechnology company, engages in developing therapeutic product candidates for inflammation and immuno-oncology indications. The company's products include Etokimab, an anti-interleukin (IL)-33 program for the treatment of atopic dermatitis, eosinophilic asthma, and chronic rhinosinusitis with nasal polyps; ANB019, an anti-IL-36 receptor for generalized pustular psoriasis and palmoplantar pustular psoriasis; and anti-inflammatory checkpoint modulators for inflammatory diseases. It is also developing immuno-oncology products, including TSR-042: anti-PD-1, TSR-022: anti-TIM-3, TSR-033: anti-LAG-3, and TSR-075: anti-PD-1/LAG-3 bispecific; and CC-90006: anti-PD-1 agonist for psoriasis, as well as other products for inflammation. AnaptysBio, Inc. has an immuno-oncology partnership with TESARO, Inc. and TESARO Development, Ltd.; collaboration with Celgene Corporation; and immuno-oncology collaboration agreement with GlaxoSmithKline plc. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was founded in 2005 and is headquartered in San Diego, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Suria HamzaPresident, CEOMar 10Option Exercise1.1210,00011,20047,636Mar 10 05:02 PM
Suria HamzaPresident, CEOFeb 05Option Exercise1.1210,00011,20037,636Feb 06 05:46 PM
Ware J. AnthonyDirectorDec 10Buy14.053,60050,5803,600Feb 06 05:48 PM